

Re: Your request made under the Freedom of Information Act 2000

This is a freedom of information request for dermatitis and asthma; please answer as many of the questions as possible. If unknown or no data, please state "not known"

- 1) How many patients were treated, in the last 3 months available for moderate or severe atopic dermatitis? Of these treated patients how many are paediatric?

We don't centrally record this information for outpatients. As for inpatients, the numbers for dermatitis patients within the last 3 months have been so low (under 5) that disclosing the data could potentially reveal the identity of the patient.

- 2) How many patients were treated, in the last 3 months available for moderate or severe atopic dermatitis with the following drugs?

Acitretin
Alitretinoin
Pimecrolimus
Tacrolimus
Dupilumab [Dupixent]
Etanercept
Infliximab
Adalimumab
Ustekinumab

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

- 3) How many patients aged 18 and over, were treated in the last 3 months available for asthma?

There were 112 inpatient spells and 972 outpatient appointments, making up a total of 1,084. For inpatients, we counted a patient as "treated for asthma" if their primary diagnosis in an episode was an asthma ICD10 code. For outpatients, we counted all appointments where asthma diagnosis code was recorded.

- 4) How many patients aged 17 and under, were treated in the last 3 months available for asthma?

There were 37 inpatient spells and 400 outpatient appointments, making up a total of 437. For inpatients, we counted a patient as "treated for asthma" if their primary diagnosis in an episode was an asthma ICD10 code. For outpatients, we counted all appointments where asthma diagnosis code was recorded.

- 5) How many asthma patients were treated in the last 3 months available with:

Omalizumab [Xolair]
Mepolizumab [Nucala]
Reslizumab [Cinqaero]
Benralizumab [Fasenra]

Unable to comment (see Q2)

- 6) How many paediatric severe asthma patients have been treated with Xolair/omalizumab in the last 3 months available?

Unable to comment (see Q2)

- 7) How many chronic spontaneous urticaria (CSU) patients have been treated with Xolair/omalizumab in the last 3 months available?

Unable to comment (see Q2)